Protagonist Therapeutics, Inc.
PTGX
$155.10
$3.682.43%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 4,204.76% | 108.52% | -12.82% | -13.14% | -198.34% |
| Total Depreciation and Amortization | -2.46% | 146.94% | -154.05% | 427.63% | 27.20% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.57% | 27.33% | 41.41% | -19.12% | -20.86% |
| Change in Net Operating Assets | 163.18% | -2,416.47% | -109.50% | 823.41% | -103.11% |
| Cash from Operations | 547.57% | -32.37% | -1,808.88% | 93.27% | -122.96% |
| Capital Expenditure | 21.86% | -49.31% | -63.64% | 89.18% | -49.17% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -102.48% | 86.09% | 183.74% | -205.11% | 159.26% |
| Cash from Investing | -102.67% | 86.20% | 183.37% | -206.83% | 158.06% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -58.32% | 723.90% | -49.87% | 93.47% | -75.47% |
| Repurchase of Common Stock | -- | -- | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -58.32% | 723.90% | -49.87% | 93.47% | -74.44% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 246.53% | 345.07% | 126.77% | -289.37% | -31.72% |